Addition of Contrast-enhanced Mammography to Tomosynthesis for Breast Cancer Detection in Women with a Personal History of Breast Cancer: Prospective TOCEM Trial Interim Analysis
Wendie A. Berg, Jeremy M Berg, Andriy I. Bandos, Adrienne Vargo, Denise M. Chough, Amy Lu, Marie A. Ganott, Amy E. Kelly, Bronwyn Nair, Jamie Y. Hartman, Uzma Waheed, Christiane M. Hakim, Kimberly Harnist, Ruthane F. Reginella, Dilip D Shinde, Bea A Carlin, Cathy S. Cohen, Luisa P. Wallace, Jules H. Sumkin, Margarita L. Zuley
Abstract
< .001). In 18 breasts with cancer detected only at CEM after integration of both observers, 13 (72%) cancers were invasive (median tumor size, 0.6 cm) and eight of nine (88%) with staging were N0. Among 1883 screenings with adequate reference standard, there were three interval cancers (one at the scar, two in axillae). Conclusion CEM added to DBT increased early breast cancer detection each year in women with PHBC, with an accompanying approximately 5.0%-6.6% recall rate increase. Clinical trial registration no. NCT04085510 © RSNA, 2024